Autonomic Nervous System Foundations and Cholinergic Pharmacology

Connect autonomic receptors, cholinergic drug mechanisms, organ effects and clinical applications into one rapid-revision framework.

1. THE TOPIC IN ONE CONNECTED FLOW

The autonomic nervous system controls involuntary organ function through acetylcholine, norepinephrine and related receptors. Cholinomimetic drugs increase cholinergic activity either by directly activating cholinergic receptors or by preventing acetylcholine breakdown. Their benefits and adverse effects can therefore be predicted from the normal distribution and function of muscarinic and nicotinic receptors.

Autonomic signalling

ACh in all preganglionic fibers; norepinephrine in most sympathetic postganglionic fibers

→

Receptor activation

Muscarinic M1–M5, nicotinic N_N/N_M, adrenergic and dopaminergic receptors

→

Cholinomimetic action

Direct receptor stimulation or acetylcholinesterase inhibition

→

Organ response

Miosis, glandular secretion, GI and bladder contraction, cardiac slowing

→

Therapeutic benefit

Glaucoma, selected urinary retention, myasthenic transmission and Alzheimer symptoms

→

Excess cholinergic effect

Bradycardia, bronchoconstriction, diarrhea, secretions and possible muscle weakness

2. KEY CLINICAL CONNECTIONS

Glaucoma and Pilocarpine

Pilocarpine → M3 receptor stimulation → ciliary muscle contraction + miosis → improved aqueous humor outflow → reduced intraocular pressure.

Cardiac Cholinergic Effects

M2 activation → reduced SA nodal firing and AV conduction → negative chronotropy + negative dromotropy → caution in bradycardia or conduction disease.

Acetylcholinesterase Inhibition

AChE inhibition → increased ACh at muscarinic and nicotinic synapses → stronger neuromuscular transmission → excessive dosing may produce secretions, fasciculations and weakness.

Myasthenic vs Cholinergic Crisis

Classical edrophonium test → transient improvement suggests inadequate neuromuscular cholinergic effect → myasthenic crisis; worsening or no improvement with cholinergic excess favors cholinergic crisis.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ All autonomic preganglionic fibers release acetylcholine → activation of neuronal nicotinic receptors in autonomic ganglia.

M2 receptors in the heart → reduced SA nodal firing and AV conduction → negative chronotropy and negative dromotropy.

M3 receptors on glands and smooth muscle → increased secretion and contraction → explains salivation, GI motility, detrusor contraction and miosis.

⭐ Direct cholinomimetics activate cholinergic receptors directly, whereas indirect cholinomimetics inhibit acetylcholinesterase → increased endogenous acetylcholine.

Resistance to cholinesterase hydrolysis → longer drug action; acetylcholine is rapidly destroyed, whereas agents such as carbachol and bethanechol persist longer.

⭐ Pilocarpine → M3 stimulation in the eye → ciliary muscle contraction and enhanced aqueous outflow → therapeutic benefit in glaucoma.

Central acetylcholinesterase inhibitors such as donepezil, rivastigmine and galantamine → increased CNS acetylcholine → symptomatic benefit in Alzheimer disease.

⭐ Exam trap: An autoreceptor responds to the transmitter released from the same nerve ending, whereas a heteroreceptor responds to a different transmitter and modifies release from that terminal.

Autonomic Nervous System Foundations and Cholinergic Pharmacology

1. THE TOPIC IN ONE CONNECTED FLOW

2. KEY CLINICAL CONNECTIONS

3. AIM HIGH-YIELD INTEGRATION REVIEW

Install AIM App